270 related articles for article (PubMed ID: 35123676)
41. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
42. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
44. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G
Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529
[TBL] [Abstract][Full Text] [Related]
45. SARS-COV-2 vaccine responses in renal patient populations.
Smith RM; Cooper DJ; Doffinger R; Stacey H; Al-Mohammad A; Goodfellow I; Baker S; Lear S; Hosmilo M; Pritchard N; Torpey N; Jayne D; Yiu V; Chalisey A; Lee J; Vilnar E; Cheung CK; Jones RB
BMC Nephrol; 2022 May; 23(1):199. PubMed ID: 35641961
[TBL] [Abstract][Full Text] [Related]
46. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.
Nguyen VG; Yavlinsky A; Beale S; Hoskins S; Byrne TE; Lampos V; Braithwaite I; Fong WLE; Fragaszy E; Geismar C; Kovar J; Navaratnam AMD; Patel P; Shrotri M; Weber S; Hayward AC; Aldridge RW
Int J Epidemiol; 2023 Apr; 52(2):342-354. PubMed ID: 36655537
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Borobia AM; Carcas AJ; Pérez-Olmeda M; Castaño L; Bertran MJ; García-Pérez J; Campins M; Portolés A; González-Pérez M; García Morales MT; Arana-Arri E; Aldea M; Díez-Fuertes F; Fuentes I; Ascaso A; Lora D; Imaz-Ayo N; Barón-Mira LE; Agustí A; Pérez-Ingidua C; Gómez de la Cámara A; Arribas JR; Ochando J; Alcamí J; Belda-Iniesta C; Frías J;
Lancet; 2021 Jul; 398(10295):121-130. PubMed ID: 34181880
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
Ergun T; Hosgoren Tekin S; Apti Sengun O; Akin Cakici O; Seckin D; Adiay C; Enul H; Yilmaz S; Ay P; Haklar G; Sili U
Vaccine; 2023 Jun; 41(29):4287-4294. PubMed ID: 37277251
[TBL] [Abstract][Full Text] [Related]
52. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
[TBL] [Abstract][Full Text] [Related]
54. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
Agrawal U; Bedston S; McCowan C; Oke J; Patterson L; Robertson C; Akbari A; Azcoaga-Lorenzo A; Bradley DT; Fagbamigbe AF; Grange Z; Hall ECR; Joy M; Katikireddi SV; Kerr S; Ritchie L; Murphy S; Owen RK; Rudan I; Shah SA; Simpson CR; Torabi F; Tsang RSM; de Lusignan S; Lyons RA; O'Reilly D; Sheikh A
Lancet; 2022 Oct; 400(10360):1305-1320. PubMed ID: 36244382
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Emary KRW; Golubchik T; Aley PK; Ariani CV; Angus B; Bibi S; Blane B; Bonsall D; Cicconi P; Charlton S; Clutterbuck EA; Collins AM; Cox T; Darton TC; Dold C; Douglas AD; Duncan CJA; Ewer KJ; Flaxman AL; Faust SN; Ferreira DM; Feng S; Finn A; Folegatti PM; Fuskova M; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hallis B; Heath PT; Hay J; Hill HC; Jenkin D; Kerridge S; Lazarus R; Libri V; Lillie PJ; Ludden C; Marchevsky NG; Minassian AM; McGregor AC; Mujadidi YF; Phillips DJ; Plested E; Pollock KM; Robinson H; Smith A; Song R; Snape MD; Sutherland RK; Thomson EC; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Williams CJ; Hill AVS; Lambe T; Gilbert SC; Voysey M; Ramasamy MN; Pollard AJ; ; ;
Lancet; 2021 Apr; 397(10282):1351-1362. PubMed ID: 33798499
[TBL] [Abstract][Full Text] [Related]
56. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
57. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis.
Yau K; Chan CT; Abe KT; Jiang Y; Atiquzzaman M; Mullin SI; Shadowitz E; Liu L; Kostadinovic E; Sukovic T; Gonzalez A; McGrath-Chong ME; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Levin A; Blake PG; Colwill K; Gingras AC; Hladunewich MA
CMAJ; 2022 Feb; 194(8):E297-E305. PubMed ID: 35115375
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
59. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
60. Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.
Kang ES; Oh JS; Lee EJ; Hong S; Ahn SM; Lee CK; Yoo B; Kim YG
J Korean Med Sci; 2023 Apr; 38(14):e109. PubMed ID: 37038645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
